US3674876A - Benzothiazine dioxides as lipid regulating agents - Google Patents

Benzothiazine dioxides as lipid regulating agents Download PDF

Info

Publication number
US3674876A
US3674876A US831768A US3674876DA US3674876A US 3674876 A US3674876 A US 3674876A US 831768 A US831768 A US 831768A US 3674876D A US3674876D A US 3674876DA US 3674876 A US3674876 A US 3674876A
Authority
US
United States
Prior art keywords
benzothiazine
dioxide
dihydro
carbon atoms
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US831768A
Inventor
Joseph G Lombardino
Gerald F Holland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of US3674876A publication Critical patent/US3674876A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame

Definitions

  • This invention relates generally to a method of regulating lipid metabolism in humans. More particularly, it is concerned with 2H-l,2-benzothiazine-l,l-dioxide derivatives, and with the effectiveness of said derivatives as lipid regulating agents.
  • regulating lipid metabolism is the ability to depress triglycerides, free fatty acids, cholesterol, lipoprotiens, phospholipids, etc. in human and animal blood.
  • novel 2I-I-l,2-benzothiazine-l,l-dioxide compounds are surprisingly useful when employed in the field of drug therapy as lipid regulating agents.
  • novel compounds of this invention are 2H-1,2-benzothiazine-l,l-dioxides of the formula:
  • X and Y are each a member selected from the group consisting of hydrogen, fluorine, chlorine, bromine, nitro, alkyl and alkoxy having from one to five carbon atoms and trifiuoromethyl;
  • R is a member selected from the group consisting of OR, and NI-IR wherein R is alkyl having from one to l2 carbon atoms or phenylalkyl having up to three carbon atoms in the alkyl moiety, and R is chosen from the group consisting of hydrogen, alkyl having from one to eight carbon atoms; alkenyl having up to six carbon atoms, cycloalkyl having up to eight carbon atoms, phenylalkyl having up to three carbon atoms in the alkyl moiety, nitrophenyl, naphthyl, phenyl, pyridyl, 3-methyl-2-pyridyl, 4-methyl-2-pyridyl
  • R is -NI-IR wherein R is a member selected from the group consisting of phenyl, nitrophenyl, pyridyl, 6-methyl-2-pyridyl, 2-pyrazinyl, 2-pyrmidyl, 2-thiazolyl, 4,5-dimethyl-2-thiazolyl, 3-isothiazolyl, 2- benzothiazolyl, 7-indazolyl and monoand di-substituted phenyl wherein each substituent is halogen, hydroxy, alkoxy and thioalkoxy having up to three carbon atoms, alkyl having up to four carbon atoms, trifluoromethyl, acetyl, methylsulfinyl or methylsulfonyl; R having from one to six carbon atoms, and Z is oxygen or sulfur.
  • Typical member compounds embraced by this invention include 3,4-dihydro2-methyl-4-oxo- 2H- 1 ,2-benzothiazine-3-carboxanilide-l l -dioxide, 3 '-chloro- 3,4-dihydro-2-methyl-4-oxo-2H- l ,2-benzothiazine-3carboxanilidel l -dioxide, 2-methoxy-3,4-dihydro-2-methyl-4-ox0- 2H- l ,2-benzothiazine-3-carboxanilide-l ,l-dioxide, 3 trifluoromethyl-3,4-dihydro-2-methyl-4oxo-2H- l ,2- benzothiazine-3-carboxanilidel l -dioxide, N-( 2-thiazolyl 3,4-dihydro- 2-methyl-4-oxo-2H- 1 ,2-benzothiazine-3-carboxamide
  • esters of this invention include those carboxylates where X and Y are each hydrogen, 2 is oxygen, R is OR wherein R is alkyl having from one to twelve carbon atoms, and R is a member selected from the group consisting of hydrogen and alkyl having from one to six carbon atoms, such as, for example, methyl-3,4-dihydro-2-methyl-4-oxo-2H-l,2- benzothiazine-3-carboxylate-1,1-dioxide and ethyl-3,4- dihydro-Z-methyl- 3-oxo-2I-I-1,2-benzothiazine-4-carboxylate-1,1-dioxide. These compounds also possess lipid regulating activity.
  • the benzothiazine dioxides of this invention can be administered either alone or preferably in combination with a pharmaceutically-acceptable carrier. They may be combined with various pharmaceutically-acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, aqueous suspensions or solutions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or filters, sterile aqueous media and various nontoxic organic solvents. Moreover, the oral pharmaceutical compositions of this invention may be suitably sweetened and flavored by means of various agents of the type commonly employed for just such a purpose.
  • solutions of suspensions of of the herein described benzothiazine dioxides in sesame or peanut oil or in aqueous propylene glycol solutions can be employed, as well as sterile aqueous solutions of the corresponding water-soluble addition salts previously enumerated.
  • These particular solutions are especially suited for intramuscular and subcutaneous injection purposes.
  • the aqueous solutions including those of the addition salts dissolved in pure distilled water, are additionally useful for intravenous injection purposes provided that their pH be properly adjusted before hand.
  • Such solutions should also be suitable buffered, if necessary, and the liquid diluent first rendered isotonic with sufi'icient saline or glucose.
  • the effective average daily dose is suitably between about 0.5 g. per day and about 3 g. per day.
  • the dosage can be taken at one time or divided dosages can be taken at different times during the day.
  • a dosage of about 73 to about 440 mg./kg. per day is appropriate.
  • the physician will determine the dosage which will be most suitable for an individual patient and it will with the age, the weight, and response of the particular patient.
  • the above dosages are exemplary of the average host. There can, of course, be individual cases where higher or lower dosage ranges are merited, and such are within the scope of this invention.
  • lipids is used here in the broad sense, covering triglycerides, cholesterol, phospholipids and free fatty acids. It is generally accepted that abnormalities in lipid metabolism, frequently indicated by elevated blood lipid levels, are closely associated with atherosclerosis, with cardiovascular disease, and with derangements of carbohydrate metabolism, e.g. diabetes. Drugs which will lower lipid levels can therefore be expected to be useful in the treatment of these diseases, and of others in which lipid metabolism is abnormal.
  • the products of this invention are tested in vivo for hypolipemic activity by measuring their ability to lower the blood lipid level of mammals. This property can be demonstrated in rats. Groups, each comprising 4 animals, normal Sprague-Dawley (Charles River) male rats weighing from l60-220 grams, are fed rat chow containing 0.25 percent of the compounds described herein for two overnight feeding periods. On the morning of the third day the animals are anesthetized and bled from the abdominal aorta. The total plasma cholesterol is then determined by the method of 1.]. Carr and LI. Drekter reported in Clin. Chem., 2, 353 (I956). The plasma cholesterol level of the treated animals is found to be significantly reduced when compared to animals not receiving the test compound,
  • a dry solid pharmaceutical composition is prepared by blending the following materials together in the proportions by weight specified below:
  • a dry solid pharmaceutical composition is prepared by combining the following materials together in the proportions by weight indicated below:
  • EXAMPLE lll Groups each comprising 4 animals, of normal Sprague- Dawley (Charles River) male rats weighing from -220 grams are fed rat chow containing 0.25 percent of the test compounds for two overnight feeding periods. On the morning of the third day the animals are anesthetized and bled from the abdominal aorta. The total plasma cholesterol is then determined by the method of 1.1. Carr and U. Drekter reported in Clin. Chem., 2, 353 (1956). The following results are obtained:
  • a method of lowering lipid levels in a human which comprises the oral or parenteral administration to a human in need of said treatment an effective amount for lowering lipid levels of a compound selected from the group consisting of or the base salts thereof with pharmacologically-acceptable cations, wherein X and Y are each a member selected from the group consisting of hydrogen, fluorine, chlorine, bromine, nitro, alkyl and alkoxy having from one to five carbon atoms, and trifluoromethyl; R is a member selected from the group consisting of OR, and Nl-lR wherein R is alkyl having from one to 12 carbon atoms or phenylalkyl having up to three carbon atoms in the alkyl moiety, and R is chosen from the group consisting of hydrogen, alkyl having from one to eight carbon atoms, alkenyl having up to six carbon atoms, cycloalkyl having up to eight carbon atoms, phenylalkyl having up to three carbon

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Certain 3,4-dihydro-4-oxo-2H-1,2-benzothiazine-3-carboxamide1,1-dioxide and 3-oxo-2H-1,2-benzothiazine-4-carboxamide-1,1dioxide compounds effective as lipid regulating agents are disclosed.

Description

United States Patent Lombardino et al.
[ 1 July 4,1972
[54] BENZOTHIAZINE DIOXIDES AS LIPID REGULATING AGENTS [72] lnventors: Joseph G. Lombardino, Niantic; Gerald F.
Holland, Old Lyme, both of Conn.
[73] Assignee: Pfizer Inc.
[22] Filed: June 9, 1969 [21] Appl. No.: 831,768
[52] US. Cl ..424/246 [51] Int. Cl. 1 ..A6lk 27/00 [58] Field of Search ..424/246; 260/243 Primary Examiner-Albert T. Meyers Assistant Examiner-Allen J. Robinson Attorney-Connolly and Hutz [57] ABSTRACT Certain 3,4-dihydr0-4-ox0-2H-l,2-benzothiazine-3-carboxamide-l,l-dioxide and 3-oxo-2H-l ,Z-benzothiazine-4-carboxamide-l,l-di0xide compounds effective as lipid regulating agents are disclosed.
36 Claims, N0 Drawings BEN ZOTIIIAZINE DIOXIDES AS LIPID REGULATING AGENTS BACKGROUND OF THE INVENTION This invention relates generally to a method of regulating lipid metabolism in humans. More particularly, it is concerned with 2H-l,2-benzothiazine-l,l-dioxide derivatives, and with the effectiveness of said derivatives as lipid regulating agents.
What is meant by the term regulating lipid metabolism" is the ability to depress triglycerides, free fatty acids, cholesterol, lipoprotiens, phospholipids, etc. in human and animal blood.
SUMMARY OF THE INVENTION In accordance with the present invention, it has been found that various novel 2I-I-l,2-benzothiazine-l,l-dioxide compounds are surprisingly useful when employed in the field of drug therapy as lipid regulating agents. The novel compounds of this invention are 2H-1,2-benzothiazine-l,l-dioxides of the formula:
and the base salts thereof with pharmacologically acceptable cations, wherein X and Y are each a member selected from the group consisting of hydrogen, fluorine, chlorine, bromine, nitro, alkyl and alkoxy having from one to five carbon atoms and trifiuoromethyl; R is a member selected from the group consisting of OR, and NI-IR wherein R is alkyl having from one to l2 carbon atoms or phenylalkyl having up to three carbon atoms in the alkyl moiety, and R is chosen from the group consisting of hydrogen, alkyl having from one to eight carbon atoms; alkenyl having up to six carbon atoms, cycloalkyl having up to eight carbon atoms, phenylalkyl having up to three carbon atoms in the alkyl moiety, nitrophenyl, naphthyl, phenyl, pyridyl, 3-methyl-2-pyridyl, 4-methyl-2-pyridyl, 5- methyl-2-pyridyl, 6-methyl-2-pyridyl, 4,6-dimethyl-2-pyridyl, 5-chloro-2-pyridyl, 5-nitro-2-pyridyl, 3-hydroxy-2-pyridyl, 5- carboxamido-Z-pyridyl, 2-pyrazinyl, 2 -pyrimidyl, 4,5- dimethyl-Z-pyrimidyl, 4-pyrimidyl, 5-methyl-3-pyridazinyl, 6- methoxy-3-pyridazinyl, l-phenyl-3-pyrazolonyl, 2-thiazolyl, 4- methyl-Z-thiazolyl, 4,5-dimethyl-2-thiazolyl, 4-phenyI-2- thiazolyl, 5-bromo-2-thiazolyl, 3-isothiazolyl, 2- benzothiazolyl, 6-methyl-2-benzothiazolyl, 4-chloro-2- benzothiazolyl, 6-bromo2-benzothiazolyl, 5-chloro-2- benzoxazolyl, 1,3,4-thiadiazolyl, S-methyll ,3,4-thiadiazolyl, 1,2,4-thiazolyl, 6-phenyl-l,2,4-triazolyl, 7-indazolyl and monoand di-substituted phenyl wherein each substituent is halogen, hydroxy, alkoxy and thioalkoxy having up to three carbon atoms, alkyl having up to four carbon atoms, trifluoromethyl, acetyl, methylsulfinyl or methylsulfonyl; R is a member selected from the group consisting of hydrogen, alkyl having from one to six carbon atoms, alkenyl having up to four carbon atoms and phenylalkyl having up to three carbon atoms in the alkyl moiety; and Z is oxygen or sulfur, except when R is OR when it is oxygen.
Of especial interest in this connection are those compounds where and Y are hydrogen, Z is oxygen, R is -NI-IR wherein R is a member selected from the group consisting of phenyl, nitrophenyl, pyridyl, 6-methyl-2-pyridyl, 2-pyrazinyl, 2-pyrmidyl, 2-thiazolyl, 4,5-dimethyl-2-thiazolyl, 3-isothiazolyl, 2- benzothiazolyl, 7-indazolyl and monoand di-substituted phenyl wherein each substituent is halogen, hydroxy, alkoxy and thioalkoxy having up to three carbon atoms, alkyl having up to four carbon atoms, trifluoromethyl, acetyl, methylsulfinyl or methylsulfonyl; R having from one to six carbon atoms, and Z is oxygen or sulfur. Typical member compounds embraced by this invention include 3,4-dihydro2-methyl-4-oxo- 2H- 1 ,2-benzothiazine-3-carboxanilide-l l -dioxide, 3 '-chloro- 3,4-dihydro-2-methyl-4-oxo-2H- l ,2-benzothiazine-3carboxanilidel l -dioxide, 2-methoxy-3,4-dihydro-2-methyl-4-ox0- 2H- l ,2-benzothiazine-3-carboxanilide-l ,l-dioxide, 3 trifluoromethyl-3,4-dihydro-2-methyl-4oxo-2H- l ,2- benzothiazine-3-carboxanilidel l -dioxide, N-( 2-thiazolyl 3,4-dihydro- 2-methyl-4-oxo-2H- 1 ,2-benzothiazine-3-carboxamidel l-dioxide, N-( Z-pyridyl)-3,4-dihydro-2-methyl-4- oxo-2H-l,2-benzothiazine-3-carboxamide-1,1-dioxide, N-( 6- methyl-2-pyridyl )-3,4-dihydro-4-oxo-2H-l ,2-benzothiazine-3- carboxamide-1,l-dioxide, 2 '4 '-dichloro-3 ,4-dihydro-2- methyl-3-oxo-2H-1,2-benzothiazine-4- carboxanilidel ,ldioxide, 4'-bromo-3 ,4-dihydro-2-methyl-3-oxo-2H- l ,2- benzothiazine-4-carboxanilide-1,1-dioxide, 2 '-chloro- 3 ,4- dihydro-2-methyl-3-oxo-2H-1,2-benzothaizine-4-carboxanilidel ,l-dioxide and 4-methylsulfonyl-3,4-dihydro-2-methyl- 3-oxo-2I-I-l,2-benzothiazine-4-carboxanilide-1,l-dioxide. It is to be understood that many of these compounds exist in the enolic form (i.e. they are tautomeric and can be 4-hydroxy or 3-hydroxy, as the case may be).
In addition, the carboxylate esters of this invention, where R.
is OR as previously defined, are extremely useful as intermediates for preparing the aforementioned carboxamide compounds via the conventional ammonolysis route using the appropriate amines. Typical and preferred esters of this invention, for use in the present connection, include those carboxylates where X and Y are each hydrogen, 2 is oxygen, R is OR wherein R is alkyl having from one to twelve carbon atoms, and R is a member selected from the group consisting of hydrogen and alkyl having from one to six carbon atoms, such as, for example, methyl-3,4-dihydro-2-methyl-4-oxo-2H-l,2- benzothiazine-3-carboxylate-1,1-dioxide and ethyl-3,4- dihydro-Z-methyl- 3-oxo-2I-I-1,2-benzothiazine-4-carboxylate-1,1-dioxide. These compounds also possess lipid regulating activity.
DETAILED DESCRIPTION OF THE INVENTION The methods of preparation and chemical properties of the benzothiazine dioxides of this invention are described in Ser. No. 767,594, filed Aug. 27, 1968, now US. Pat. No. 3,591,584. Included within the scope of the designated compounds are the pharmaceutically-acceptable acid addition salts.
The benzothiazine dioxides of this invention can be administered either alone or preferably in combination with a pharmaceutically-acceptable carrier. They may be combined with various pharmaceutically-acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, aqueous suspensions or solutions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or filters, sterile aqueous media and various nontoxic organic solvents. Moreover, the oral pharmaceutical compositions of this invention may be suitably sweetened and flavored by means of various agents of the type commonly employed for just such a purpose.
For purposes of parenteral administration, solutions of suspensions of of the herein described benzothiazine dioxides in sesame or peanut oil or in aqueous propylene glycol solutions can be employed, as well as sterile aqueous solutions of the corresponding water-soluble addition salts previously enumerated. These particular solutions are especially suited for intramuscular and subcutaneous injection purposes. The aqueous solutions, including those of the addition salts dissolved in pure distilled water, are additionally useful for intravenous injection purposes provided that their pH be properly adjusted before hand. Such solutions should also be suitable buffered, if necessary, and the liquid diluent first rendered isotonic with sufi'icient saline or glucose.
When administered to humans orally or parenterally, the effective average daily dose is suitably between about 0.5 g. per day and about 3 g. per day. The dosage can be taken at one time or divided dosages can be taken at different times during the day. On a body weight basis, a dosage of about 73 to about 440 mg./kg. per day is appropriate.
The physician will determine the dosage which will be most suitable for an individual patient and it will with the age, the weight, and response of the particular patient. The above dosages are exemplary of the average host. There can, of course, be individual cases where higher or lower dosage ranges are merited, and such are within the scope of this invention.
The term lipids is used here in the broad sense, covering triglycerides, cholesterol, phospholipids and free fatty acids. It is generally accepted that abnormalities in lipid metabolism, frequently indicated by elevated blood lipid levels, are closely associated with atherosclerosis, with cardiovascular disease, and with derangements of carbohydrate metabolism, e.g. diabetes. Drugs which will lower lipid levels can therefore be expected to be useful in the treatment of these diseases, and of others in which lipid metabolism is abnormal.
The products of this invention are tested in vivo for hypolipemic activity by measuring their ability to lower the blood lipid level of mammals. This property can be demonstrated in rats. Groups, each comprising 4 animals, normal Sprague-Dawley (Charles River) male rats weighing from l60-220 grams, are fed rat chow containing 0.25 percent of the compounds described herein for two overnight feeding periods. On the morning of the third day the animals are anesthetized and bled from the abdominal aorta. The total plasma cholesterol is then determined by the method of 1.]. Carr and LI. Drekter reported in Clin. Chem., 2, 353 (I956). The plasma cholesterol level of the treated animals is found to be significantly reduced when compared to animals not receiving the test compound,
The following examples are provided by way of illustration, and should not be interpreted as limiting the invention, many variations of which are possible without departing from the spirit or scope thereof.
EXAMPLE I A dry solid pharmaceutical composition is prepared by blending the following materials together in the proportions by weight specified below:
l,2-dihydro-4-hydroxy-2-methyll ,Z-benzothiazine 3(P-tolylcarboxanilide)-l,l-dioxide 50 Sodium citrate 25 Alginic acid 10 Polyvinylpyrrolidone Magnesium stearate 5 EXAMPLE ll A dry solid pharmaceutical composition is prepared by combining the following materials together in the proportions by weight indicated below:
benzothiazine-4-carboxanilidel l dioxide 50 Calcium carbonate 20 Polyethylene glycol, average molecular weight 4000 30 The dried solid mixture so prepared is then throughly agitated so as to obtain a powdered product that is completely uniform. Soft elastic and hardfilled gelatin capsules containing this pharmaceutical composition are then prepared, employing a sufficient quantity of material in each case so as to provide each capsule with 190 mg. of the active ingredient.
EXAMPLE lll Groups, each comprising 4 animals, of normal Sprague- Dawley (Charles River) male rats weighing from -220 grams are fed rat chow containing 0.25 percent of the test compounds for two overnight feeding periods. On the morning of the third day the animals are anesthetized and bled from the abdominal aorta. The total plasma cholesterol is then determined by the method of 1.1. Carr and U. Drekter reported in Clin. Chem., 2, 353 (1956). The following results are obtained:
Compound 71 Cholesterol Fall l,2-dihydro-4-hydroxy-2-methyll ,2- benzothiazine-3(p-toluidide l l -dioxide 3,4'-dichloro-4-hydroxy-Z-methyl-ZH- l,2benzothiazine-S-carboxanilidel l dioxide 2-chIoro-4-hydroxy-Z-methyl-ZH- l ,2-
benzothiazine-3-carboxanilidel ldioxide 4'-bromo-4hydroxy-2-methyl-2H-1,2- benzothiazine-3-carboxanilidel l dioxide 2-methyl-3-chloro-4hydroxy-2H-l,2
benzothiazine-3-o-toluidide l l -dioxide -carboxa- 4-acetyl-4-hydroxy-2-methyl-2H- l ,2-
benzothiazine-carboxanilidel l -dioxide 2,2,5'-trimethyl-4'-nitro-4-hydroxy- 2H- 1 ,2-benzothiazine-3-carboxanilide-l, l dioxide 2',4',5-trichloro-4-hydroxy-2-methyl-2H-1,2- benzothiazine-3-carboxanilide-l l -dioxide N-( S-methyll ,3,4-thiadiazol-2-yl )-4- hydroxy-Z-methyl-ZH- l ,Z-benzothiazine- 3-carboxamidel ldioxide N(4-methyl-2-pyridyl)-4-hydroxy-2- methyl-2H- l ,2benzothia2ine-3-carboxzmide-l,l-dioxide N-(S-bromo-Z-pyridyl)-4-hydroxy-2- methyl-2H- l ,2benzothiazine-3-carboxamide-l,l-dioxide 4-hydroxy-2-methyl-N-[6-methyl2-benzo thiazolyl )-2H- l ,2-ben2othiazine-3- carboxamidel l -dioxide N-( 6-bromo-2benzothiazolyl )-4-hydroxy 2-methyl-2H- l ,2-benzothiazine-3-carboxamidel l-dioxide 3,5-dihydro-2-methyl3-oxo-2H- l ,2-benzothiazine-4-(p-anisidide)-l l -dioxide 3,4-dihydro-2methyl-3-oxo 2H- l ,Z-benzothiazine-4-( p-toluidide l l-dioxide 3,4dihydro-2-methyl-N-( l-naphthyl)-3- oxo-ZH- l ,2-benzothiazine-4-carboxamide-l,l-dioxide 3,4-dihydro-4'ethoxy-2-methyl3-oxo- 2H- 1 ,2-benzothiazine-4-carboxanilidel, l -dioxide 3,4'-dichloro-3,4-dihydro-2methyl-3- oxo-ZH- l ,2-benzothiazine-4-carboxanilide-l,l-dioxide 2-benzyl-4'-chloro-3,4-dihydro-3-oxo- 2H- 1 ,2-benzothiazine-4-carboxanilidel, l -dioxide 3,4-dihydro-2-methyl-3'-trifluoromethyl- 3-oxo-2H l ,2-benzothiazine-4-carboxanilidel l -dioxide 2-benzyl-2',4'-dichloro-3,4-dihydro-3- oxo-ZH- l ,2-benzothiazine-4-carboxanilidel l dioxide 3'-chloro-3,4-dihydro-2,4'-dimethyl-3- oxol ,2-benzothiazine-4-carboxanilidel,1-dioxide 4'-acetyl-3,4'dihydro-2-methyl-3-oxo- 2H-l ,2'benzothiazine-4-carboxanilidel,l-dioxide 4-hydroxy-2-methyll ,2-benzothiazine-3- thiocarboxanilidel l -dioxide 4'-bromo-3,4-dihydro-2,7-dimethyl-3- oxol ,2-benzothiazine-4-carboxanilidel, l -dioxide The remaining compounds of this invention cause a drop in plasma cholesterol levels in a comparable percentage range.
What is claimed is:
l. A method of lowering lipid levels in a human which comprises the oral or parenteral administration to a human in need of said treatment an effective amount for lowering lipid levels of a compound selected from the group consisting of or the base salts thereof with pharmacologically-acceptable cations, wherein X and Y are each a member selected from the group consisting of hydrogen, fluorine, chlorine, bromine, nitro, alkyl and alkoxy having from one to five carbon atoms, and trifluoromethyl; R is a member selected from the group consisting of OR, and Nl-lR wherein R is alkyl having from one to 12 carbon atoms or phenylalkyl having up to three carbon atoms in the alkyl moiety, and R is chosen from the group consisting of hydrogen, alkyl having from one to eight carbon atoms, alkenyl having up to six carbon atoms, cycloalkyl having up to eight carbon atoms, phenylalkyl having up to three carbon atoms in the alkyl moiety, phenyl, nitrophenyl, naphthyl, pyridyl, 3-methyl-2-pyridyl, 4-methyl-2-pyridyl, 5- methyl-2-pyridyl, 6-methyl-2-pyridyl, 4,6-dimethyl-2-pyridyl, 5-chloro-2-pyridyl, 5-bromo-2-pyridyl, 5-nitro-2-pyridyl, 3- hydroxy-2-pyridyl, 5-carboxamido-2-pyridyl, 2-pyrazinyl, 2- pyrimidyl, 4,5-dimethyl-2-pyrimidyl, 4-pyrimidyl, 5-methyl-3- pyridazinyl, 6-methoxy-3-pyridazinyl, 1-phenyl-3-pyrazolonyl, 2-thiazolyl, 4-methyl-2-thiazolyl, 4-phenyl-2-thiazolyl, 5- brorno-Z-thiazolyl, 4,5-dimethyl-2-thiazolyl, 3-isothiazoyl, 2- benzothiazolyl, 6-methyl-2-benzothiazolyl, 4 chloro-2- benzothiazolyl, 6-bromo-2-benzothiazolyl, 5-chloro-2- benzoxazolyl, 1,3,4-thiadiazolyl, S-methyl-l ,3,4-thiadiazolyl, 1,2,4-triazolyl, 6-phenyl-I,2,4-triazolyl, 7-indazolyl, monoand di-substituted phenyl wherein each substitutent is halogen, hydroxy, alkoxy or thioalkoxy having up to three carbon atoms, alkyl having up to four carbon atoms, trifluoromethyl, acetyl, methylsulfinyl or methylsulfonyl; R is a member selected from the group consisting of hydrogen, alkyl having from one to six carbon atoms, alkenyl having up to four carbon atoms and phenylalkyl having up to three carbon atoms in the alkyl moiety; and Z is oxygen or sulfur, ex-
cept when R is ---OR when it is oxygen.
2. The method of claim 1 wherein said compound is a 3,4- dihydro-4-oxo-2H-l ,2-benzothiazine-3-carboxamide-l,1- dioxide having the first formula wherein R is NHR 3. The method of claim 2 wherein said compound is a 3,4- dihydro-4-oxo-2H-1 ,2-benzothiazine-3-carboxamidel l dioxide wherein X and Y are each hydrogen, 2 is oxygen, R is phenyl and R is alkyl of from one to six carbon atoms.
4 The method of claim 2 wherein said compound is a 3,4- dihydro-4-oxo-2H-l,2benzothiazine3-carboxamide-1,1-dioxide wherein X and Y are each hydrogen, 2 is sulfur, R is phenyl and R is alkyl of from one to six carbon atoms.
5. The method of claim 2 wherein said compound is a 3,4- dihydro-4-oxo-2l-ll ,2benzothiazine-3-carboxamidel l -dioxide wherein X and Y are each hydrogen, Z is oxygen, R is chlorophenyl and R is alkyl of from one to six carbon atoms.
6. The method of claim 2 wherein said compound is a 3,4- dihydro-4-oxo-2l-l1,2-benzothiazine-3-carboxamide-l,ldioxide wherein X and Y are each hydrogen, 2 is oxygen, R is phenylalkyl having up to three carbon atoms in the alkyl moiety and R, is alkyl of from one to six carbon atoms.
7. The method of claim 2 wherein said compound is a 3,4- dihydro-4-oxo-2l-l-l,2-benzothiazine-3-carboxamide-1,1- dioxide wherein X and Y are each hydrogen, Z is oxygen, R is alkenyl having up to six carbon atoms and R is alkyl of from one to six carbon atoms.
8. The method of claim 2 wherein said compound is a 3,4- dihydro-4-oxo-2l-l-l,2-benzothiazine-3-carboxamide-1,1- dioxide wherein Xand Y are each hydrogen, Z is oxygen, R is cycloalkyl having up to eight carbon atoms and R is alkyl of from one to six carbon atoms.
9. The method of claim 2 wherein said compound is a 3,4- dihydro-4-oxo-2H- l ,2-benzothiazine'3-carboxamidel l dioxide wherein X and Y are each hydrogen, 2 is oxygen, R is dichlorophenyl and R is alkyl of from one to six carbon atoms.
10. The method of claim 2 wherein said compound is a 3,4- dihydro-4-oxo-2H- l ,2-benzothiazine-3-carboxamidel l dioxide wherein X and Y are each hydrogen, 2 is oxygen, R is chlorophenyl and R is hydrogen.
11. The method of claim 2 wherein said compound is a 3,4- dihydro-4-oxo-2l-ll ,2-benzothiazine-3-carboxamidel l dioxide wherein X and Y are each hydrogen, 2 is oxygen, R is 2-thiazolyl and R is alkyl of from one to six carbon atoms.
12. The method of claim 2 wherein said compound is a 3,4- dihydro-4oxo-2H-l,2-benzothiazine-3-carboxamide-1,l dioxide wherein X and Y are each hydrogen, 2 is oxygen, R is pyridyl and R is alkyl of from one to six carbon atoms.
13. The method of claim 2 wherein said compound is a 3,4- dihydro-4-oxo-2H- l ,2-benzothiazine-3-carboxamidel l dioxide wherein X and Y are each hydrogen, 2 is oxygen, R is monomethyl Z-pyridyl and R is alkyl of from one to six carbon atoms.
14. The method of claim 1 wherein said compound is a 3,4- dihydro-4-oxo-2H- l ,2-benzothiazine-3-carboxylatel 1 -dioxide having the first formula wherein R is OR, and Z is oxygen.
15. The method of claim 14 wherein said compound is a 3 ,4-dihydro-4-oxo-2H- l ,2-benzothiazine-3-carboxylatel ldioxide wherein X and Y are each hydrogen, R is alkyl having from one to 12 carbon atoms and R is alkyl of from one to six carbon atoms. I I
16. The method of claim 14 wherein said compound is a 3,4-dihydro-4-oxo-2H-1,2-benzothiazine-3-carboxylate-1 1 dioxide wherein X and Y are hydrogen, R is alkyl having from one to 12 carbon atoms and R is hydrogen.
17. The method of claim 1 wherein said compound is a 3,4- dihydro-3-oxo-2H- l ,2-benzothiazine-4-carboxamidel l dioxide having the second formula wherein R is NHR 18. The method of claim 17 wherein said compound is a 3,4-dihydro-3-oxo-2H- l ,2-benzothiazine-4-carboxamide-l ,ldioxide wherein X and Y are each hydrogen, Z is oxygen, R is phenyl and R is alkyl of from one to six carbon atoms.
19. The method of claim 17 wherein said compound is a 3,4-dihydro-3-oxo-2H-1,Z-benzothiazine-4-carboxamide-l ,ldioxide wherein X and Y are each hydrogen, Z is oxygen, R is chlorophenyl and R is alkyl of from one to six carbon atoms.
20. The method of claim 17 wherein said compound is a 3 ,4-dihydro-3-oxo-2H- l ,2-benzothiazine-4-carboxamide-l ,1- dioxide wherein X and Y are each hydrogen, Z is oxygen, R is pyridyl and R is alkyl of from one to six carbon atoms.
21. The method of claim 17 wherein said compound is a 3 ,4-dihydro-3-oxo-2H- l ,2-benzothiazine-4-carboxamide-l ,ldioxide wherein X and Y are each hydrogen, 2 is oxygen, R is dichlorophenyl and R is alkyl having from one to six carbon atoms.
22. The method of claim 17 wherein said compound is a 3 ,4-dihydro-3-oxo-2H- l ,2-benzothiazine-4-carboxamidel l dioxide wherein X and Y are each hydrogen, 2 is oxygen, R is -bromophenyl and R is alkyl of from one to six carbon atoms.
23. The method of claim .17 wherein said compound is a 3 ,4-dihydro-3-oxo-2l-ll ,2-benzothiazine-4-carboxamidel l dioxide wherein X and Y are each hydrogen, Z is oxygen, R is naphthyl and R is alkyl of from one to six carbon atoms.
24. The method of claim 17 wherein said compound is a 3,4-dihydro-3-oxo-21-ll ,2-benzothiazine-4-carboxamidel ,1- dioxide wherein X and Y are each hydrogen, 2 is oxygen, R is alkyl having from one to eight carbon atoms and R is alkyl of from one to six carbon atoms.
25. The method of claim 17 wherein said compound is a 3,4-dihydro-3-oxo-2H- l ,2-benzothiazine-4-carboxamide-l l dioxide wherein X is hydrogen, Y is alkyl having from one to five carbon atoms, Z is oxygen, R is dichlorophenyl and R is alkyl of from one to six carbon atoms.
26. The method of claim 17 wherein said compound is a 3,4-dihydro-3-oxo-2H-l ,2-benzothiazine-4-carboxamide-1,1- dioxide wherein X is hydrogen, Y is alkyl having from one to five carbon atoms, Z is oxygen, R is bromophenyl and R is alkyl of from one to six carbon atoms.
27. The method of claim 17 wherein said compound is a 3 ,4-dihydro-3-oxo-2H-l,2-benzothiazine-4-carboxamide-1,ldioxide wherein X and Y are each hydrogen, Z is oxygen, R is phenyl and R is phenylalkyl having up to three carbon atoms in the alkyl moiety.
28. The method of claim 17 wherein said compound is a 3,4-dihydro-3oxo-2l-l-l,2-benzothiazine-4-carboxamide-1,1- dioxide wherein X and Y are each hydrogen, Z is oxygen, R is 2-thiazolyl and R is alkyl of from one to six carbon atoms.
29. The method of claim 1 wherein said compound is a 3,4- dihydro-3-oxo-2H- l ,2-benzothiazine-4-carboxylatel l-dioxide having the second formula wherein R is OR and Z is oxygen.
30. The method of claim 29 wherein said compound is a 3 ,4-dihydro-3-oxo-2H- l ,2-benzothiazine-4-carboxylatel ldioxide wherein X and Y are each hydrogen, R is alkyl having from one to 12 carbon atoms and R is alkyl of from one to six carbon atoms.
31. The method of claim 17 wherein said compound is 3,4- dihydro-4'-eth0xy-2-methyl-3-0x0-2Hl ,2-benzothiazine-4- carboxanilide -l,1-dioxide.
32. The method of claim 17 wherein said compound is 2- benzyl-4-chloro-3,4-dihydro-3-oxo-2H- l ,2-benzothiazine-4- carboxanilidel 1 -dioxide. 1
33. The method ofclaim 2 wherein said compound is 22 ',5' -trimethyl-4 -nitro-4-hydroxy-2H- l ,2-benzothiazine-3-carboxanilidel l -dioxide.
34. The method of claim 17 wherein said compound is 2- benzyl-2,4-dichloro-3,4-dihydro-3-oxo-2H- 1 ,2- benzothiazine-4-carboxanilidel l -dioxide.
35. The method of claim 2 wherein said compound is 4- hydroxy-2-methyl-N-( 6-methyl-2-benzothiazolyl )-2H- 1 ,2- benzothiazine-3-carboxamide-1,-l-dioxide.
36. The method of claim 2 wherein said compound is N-( 6- bromo-2-benzothiazolyl)-4-hydroxy-2-methyl-2H- l ,2- benzothiazine-3-carboxamidel l-dioxide.

Claims (35)

  1. 2. The method of claim 1 wherein said compound is a 3,4-dihydro-4-oxo-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide having the first formula wherein R is -NHR2.
  2. 3. The method of claim 2 wherein said compound is a 3,4-dihydro-4-oxo-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide wherein X and Y are each hydrogen, Z is oxygen, R2 is phenyl and R3 is alkyl of from one to six carbon atoms.
  3. 4. The method of claim 2 wherein said compound is a 3,4-dihydro-4-oxo-2H-1,2benzothiazine3-carboxamide-1,1-dioxide wherein X and Y are each hydrogen, Z is sulfur, R2 is phenyl and R3 is alkyl of from one to six carbon atoms.
  4. 5. The method of claim 2 wherein said compound is a 3,4-dihydro-4-oxo-2H-1,2benzothiazine-3-carboxamide-1,1-dioxide wherein X and Y are each hydrogen, Z is oxygen, R2 is chlorophenyl and R3 is alkyl of from one to six carbon atoms.
  5. 6. The method of claim 2 wherein said compound is a 3,4-dihydro-4-oxo-2H-1,2-benzothiazine-3-carboxamide-1,1dioxide wherein X and Y are each hydrogen, Z is oxygen, R2 is phenylalkyl having up to three carbon atoms in the alkyl moiety and R3 is alkyl of from one to six carbon atoms.
  6. 7. The method of claim 2 wherein said compound is a 3,4-dihydro-4-oxo-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide wherein X and Y are each hydrogen, Z is oxygen, R2 is alkenyl having up to six carbon atoms and R3 is alkyl of from one to six carbon atoms.
  7. 8. The method of claim 2 wherein said compound is a 3,4-dihydro-4-oxo-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide wherein X and Y are each hydrogen, Z is oxygen, R2 is cycloalkyl having up to eight carbon atoms and R3 is alkyl of from one to six carbon atoms.
  8. 9. The method of claim 2 wherein said compound is a 3,4-dihydro-4-oxo-2H-1,2-benzothiazine-3-carboxamide-1,1dioxide wherein X and Y are each hydrogen, Z is oxygen, R2 is dichlorophenyl and R3 is alkyl of from one to six carbon atoms.
  9. 10. The method of claim 2 wherein said compound is a 3,4-dihydro-4-oxo-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide wherein X and Y are each hydrogen, Z is oxygen, R2 is chlorophenyl and R3 is hydrogen.
  10. 11. The method of claim 2 wherein said compound is a 3,4-dihydro-4-oxo-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide wherein X and Y are each hydrogen, Z is oxygen, R2 is 2-thiazolyl and R3 is alkyl of from one to six carbon atoms.
  11. 12. The method of claim 2 wherein said compound is a 3,4-dihydro-4-oxo-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide wherein X and Y are each hydrogen, Z is oxygen, R2 is pyridyl and R3 is alkyl of from one to six carbon atoms.
  12. 13. The method of claim 2 wherein said compound is a 3,4-dihydro-4-oxo-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide wherein X and Y are each hyDrogen, Z is oxygen, R2 is monomethyl 2-pyridyl and R3 is alkyl of from one to six carbon atoms.
  13. 14. The method of claim 1 wherein said compound is a 3,4-dihydro-4-oxo-2H-1,2-benzothiazine-3-carboxylate-1,1-dioxide having the first formula wherein R is OR1 and Z is oxygen.
  14. 15. The method of claim 14 wherein said compound is a 3,4-dihydro-4-oxo-2H-1,2-benzothiazine-3-carboxylate-1,1-dioxide wherein X and Y are each hydrogen, R1 is alkyl having from one to 12 carbon atoms and R3 is alkyl of from one to six carbon atoms.
  15. 16. The method of claim 14 wherein said compound is a 3,4-dihydro-4-oxo-2H-1,2-benzothiazine-3-carboxylate-1,1dioxide wherein X and Y are hydrogen, R1 is alkyl having from one to 12 carbon atoms and R3 is hydrogen.
  16. 17. The method of claim 1 wherein said compound is a 3,4-dihydro-3-oxo-2H-1,2-benzothiazine-4-carboxamide-1,1-dioxide having the second formula wherein R is -NHR2.
  17. 18. The method of claim 17 wherein said compound is a 3,4-dihydro-3-oxo-2H-1,2-benzothiazine-4-carboxamide-1,1-dioxide wherein X and Y are each hydrogen, Z is oxygen, R2is phenyl and R3 is alkyl of from one to six carbon atoms.
  18. 19. The method of claim 17 wherein said compound is a 3,4-dihydro-3-oxo-2H-1,2-benzothiazine-4-carboxamide-1,1-dioxide wherein X and Y are each hydrogen, Z is oxygen, R2 is chlorophenyl and R3 is alkyl of from one to six carbon atoms.
  19. 20. The method of claim 17 wherein said compound is a 3,4-dihydro-3-oxo-2H-1,2-benzothiazine-4-carboxamide-1,1-dioxide wherein X and Y are each hydrogen, Z is oxygen, R2 is pyridyl and R3 is alkyl of from one to six carbon atoms.
  20. 21. The method of claim 17 wherein said compound is a 3,4-dihydro-3-oxo-2H-1,2-benzothiazine-4-carboxamide-1,1-dioxide wherein X and Y are each hydrogen, Z is oxygen, R2 is dichlorophenyl and R3 is alkyl having from one to six carbon atoms.
  21. 22. The method of claim 17 wherein said compound is a 3,4-dihydro-3-oxo-2H-1,2-benzothiazine-4-carboxamide-1,1-dioxide wherein X and Y are each hydrogen, Z is oxygen, R2 is bromophenyl and R3 is alkyl of from one to six carbon atoms.
  22. 23. The method of claim 17 wherein said compound is a 3,4-dihydro-3-oxo-2H-1,2-benzothiazine-4-carboxamide-1,1-dioxide wherein X and Y are each hydrogen, Z is oxygen, R2 is naphthyl and R3 is alkyl of from one to six carbon atoms.
  23. 24. The method of claim 17 wherein said compound is a 3,4-dihydro-3-oxo-2H-1,2-benzothiazine-4-carboxamide-1,1-dioxide wherein X and Y are each hydrogen, Z is oxygen, R2 is alkyl having from one to eight carbon atoms and R3 is alkyl of from one to six carbon atoms.
  24. 25. The method of claim 17 wherein said compound is a 3,4-dihydro-3-oxo-2H-1,2-benzothiazine-4-carboxamide-1,1-dioxide wherein X is hydrogen, Y is alkyl having from one to five carbon atoms, Z is oxygen, R2 is dichlorophenyl and R3 is alkyl of from one to six carbon atoms.
  25. 26. The method of claim 17 wherein said compound is a 3,4-dihydro-3-oxo-2H-1,2-benzothiazine-4-carboxamide-1,1-dioxide wherein X is hydrogen, Y is alkyl having from one to five carbon atoms, Z is oxygen, R2 is bromophenyl and R3 is alkyl of from one to six carbon atoms.
  26. 27. The method of claim 17 wherein said compound is a 3,4-dihydro-3-oxo-2H-1,2-benzothiazine-4-carboxamide-1,1-dioxide wherein X and Y are each hydrogen, Z is oxygen, R2 is phenyl and R3 is phenylalkyl having up to three carbon atoms in the alkyl moiety.
  27. 28. The method of claim 17 wherein said compound is a 3,4-dihydro-3oxo-2H-1,2-benzothiazine-4-carboxamide-1,1-dioxide wherein X and Y are each hydrogen, Z is oxygen, R2 is 2-thiazolyl and R3 is alkyl of from one to six carbon atoms.
  28. 29. The method of claim 1 wherein said compound is a 3,4-dihydro-3-oxo-2H-1,2-benzothiazine-4-carboxylate-1,1-dioxide having the second formula wherein R is OR1 and Z is oxygen.
  29. 30. The method of claim 29 wherein said compound is a 3,4-dihydro-3-oxo-2H-1,2-benzothiazine-4-carboxylate-1,1-dioxide wherein X and Y are each hydrogen, R1 is alkyl having from one to 12 carbon atoms and R3 is alkyl of from one to six carbon atoms.
  30. 31. The method of claim 17 wherein said compound is 3,4-dihydro-4''-ethoxy-2-methyl-3-oxo-2H-1,2-benzothiazine-4-carboxanilide -1, 1-dioxide.
  31. 32. The method of claim 17 wherein said compound is 2-benzyl-4''-chloro-3,4-dihydro-3-oxo-2H-1,2-benzothiazine-4-carboxanilide-1, 1-dioxide.
  32. 33. The method of claim 2 wherein said compound is 2,2'',5''-trimethyl-4''-nitro-4-hydroxy-2H-1,2-benzothiazine-3-carboxanilide -1,1-dioxide.
  33. 34. The method of claim 17 wherein said compound is 2-benzyl-2'', 4''-dichloro-3,4-dihydro-3-oxo-2H-1,2-benzothiazine-4-carboxanilide-1,1 -dioxide.
  34. 35. The method of claim 2 wherein said compound is 4-hydroxy-2-methyl-N-(6-methyl-2-benzothiazolyl)-2H-1,2-benzothiazine-3 -carboxamide-1,1-dioxide.
  35. 36. The method of claim 2 wherein said compound is N-(6-bromo-2-benzothiazolyl)-4-hydroxy-2-methyl-2H-1,2-benzothiazine-3 -carboxamide-1,1-dioxide.
US831768A 1969-06-09 1969-06-09 Benzothiazine dioxides as lipid regulating agents Expired - Lifetime US3674876A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83176869A 1969-06-09 1969-06-09

Publications (1)

Publication Number Publication Date
US3674876A true US3674876A (en) 1972-07-04

Family

ID=25259819

Family Applications (1)

Application Number Title Priority Date Filing Date
US831768A Expired - Lifetime US3674876A (en) 1969-06-09 1969-06-09 Benzothiazine dioxides as lipid regulating agents

Country Status (1)

Country Link
US (1) US3674876A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761424A (en) * 1985-10-01 1988-08-02 Warner-Lambert Company Enolamides, pharmaceutical compositions and methods for treating inflammation
WO1990009794A1 (en) * 1989-02-28 1990-09-07 Nippon Hypox Laboratories Incorporated Remedy for diabetes
US20050277635A1 (en) * 2004-05-19 2005-12-15 Boehringer Ingelheim International Gmbh Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492299A (en) * 1968-02-21 1970-01-27 Mcneilab Inc Benzothiazine dioxide carboxylates
US3501466A (en) * 1967-11-30 1970-03-17 Mcneilab Inc 3-carbamoyl and 3-alkoxycarbonyl benzothiazine-1,1-dioxides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3501466A (en) * 1967-11-30 1970-03-17 Mcneilab Inc 3-carbamoyl and 3-alkoxycarbonyl benzothiazine-1,1-dioxides
US3492299A (en) * 1968-02-21 1970-01-27 Mcneilab Inc Benzothiazine dioxide carboxylates

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761424A (en) * 1985-10-01 1988-08-02 Warner-Lambert Company Enolamides, pharmaceutical compositions and methods for treating inflammation
WO1990009794A1 (en) * 1989-02-28 1990-09-07 Nippon Hypox Laboratories Incorporated Remedy for diabetes
US20050277635A1 (en) * 2004-05-19 2005-12-15 Boehringer Ingelheim International Gmbh Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds
US20060040928A1 (en) * 2004-05-19 2006-02-23 Boehringer Ingelheim Vetmedica Gmbh Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds
US20080139541A1 (en) * 2004-05-19 2008-06-12 Klaus Bornemann Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds
US7393843B2 (en) 2004-05-19 2008-07-01 Boehringer Ingelheim International Gmbh Method of treating diseases and conditions associated with an altered level of amyloid β peptides and new enolcarboxamide compounds
US20090099159A1 (en) * 2004-05-19 2009-04-16 Boehringer Ingelheim International Gmbh Method of Treating Diseases and Conditions Associated with an Altered Level of Amyloid Beta Peptides and New Enolcarboxamide Compounds
US7534787B2 (en) 2004-05-19 2009-05-19 Boehringer Ingelheim International Gmbh Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds

Similar Documents

Publication Publication Date Title
EP0753298B1 (en) Synergistic combination comprising an insulin sensitizer and a HMG-CoA reductase inhibitor for treating arteriosclerosis
AU688739B2 (en) Method and composition for the treatment of Parkinson's disease
AU754064B2 (en) Anti-inflammatory eye drops
KR950702982A (en) Substituted Thiazolidinedione Derivatives
PT1637138E (en) Use of thiazolidinediones to prevent or delay onset of niddm
KR20050061501A (en) Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses threreof
SK287063B6 (en) N-[2-hydroxy-3-(1-piperidinyl)-propoxy]pyridine-1-oxide-3- carboximidoyl chloride, its use in the treatment of insulin resistance and pharmaceutical composition containing thereof
US5886023A (en) Agent for improving dementia
US4447443A (en) Anti-inflammatory/analgesic combination of α-fluoromethylhistidine and a selected non-steroidal anti-inflammatory drug (NSAID)
US3674876A (en) Benzothiazine dioxides as lipid regulating agents
DE69710111T2 (en) Treatment and prophylaxis of pancreatitis
CZ2000324A3 (en) Use of chromium and pharmaceutical preparation
GB2184653A (en) Dementia improving and therapeutic agents
EP0004187B1 (en) Heterocyclylcarbonyl derivatives of urea and their use as agents for dissolution of gallstones
KR850001933B1 (en) Process for preparing 2-substituted-phenylthiazole derivatives
DE69925578T2 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING DISEASES RELATED TO EYE-BASED CELL-DISEASES
CA2554082C (en) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
JPH0610132B2 (en) Diabetic cataract drug
JPS6263517A (en) Remedy for hepatic disease
EP0841913B1 (en) Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
KR900006993B1 (en) Dl-5-(2-benzyl-3,4-dihydro-2h-benzo pyrano-6-yl)methyl thiazolidine-2,4-dione as an antiatherosclerosis agent
DE3508665A1 (en) HETEROCYCLIC SULFIDES AND THEIR USE AS IMMUNO MODULATORS
HUT50440A (en) Process for producing pharmaceutical compositions for treating schizophrenia
Kanterewicz et al. Bezafibrate induced rhabdomyolysis.
US4339452A (en) Methods of inhibiting blood platelet aggregation with caroverine fumarate